Core Viewpoint - Chengdu Huashen Technology Group Co., Ltd. plans to transfer its 51% stake in Tibet Kangyu Pharmaceutical Co., Ltd., and an asset evaluation report has been prepared to assess the market value of the entire equity of Tibet Kangyu Pharmaceutical as of April 30, 2025 [1][4][17]. Group 1: Evaluation Purpose and Scope - The purpose of the asset evaluation is to provide a market value reference for the transfer of the 51% stake in Tibet Kangyu Pharmaceutical, which has been approved by the management of Chengdu Huashen Technology Group [4][15]. - The evaluation object includes all equity of Tibet Kangyu Pharmaceutical related to the 51% stake being transferred, and the evaluation scope encompasses all assets and liabilities reported by Tibet Kangyu as of the evaluation benchmark date [5][17]. Group 2: Financial Overview - As of April 30, 2025, the book value of the equity of Tibet Kangyu Pharmaceutical included in the evaluation is 47.6827 million RMB [5][18]. - The total assets of Tibet Kangyu Pharmaceutical as of the evaluation date are 122.8727 million RMB, with current assets amounting to 121.7788 million RMB and non-current assets at 1.0940 million RMB [18]. - The total liabilities amount to 75.1900 million RMB, with current liabilities at 74.0933 million RMB and non-current liabilities at 1.0967 million RMB [18]. Group 3: Financial Performance - The operating income for the year 2022 was 367.0327 million RMB, with a net profit of 103.825 million RMB [14]. - For the year 2023, the operating income was 368.7942 million RMB, and the net profit was 174.047 million RMB [14]. - The projected operating income for the first four months of 2025 is 220.4142 million RMB, with a net profit of 28.961 million RMB [14].

Audit Opinion - The audit report states that the financial statements of Tibet Kangyu Pharmaceutical Co., Ltd. fairly reflect its financial position as of December 31, 2024, and April 30, 2025, in accordance with accounting standards [2][3]. Company Overview - Tibet Kangyu Pharmaceutical Co., Ltd. was established on March 18, 2015, with a registered capital of RMB 10 million, fully paid [5]. - The company operates in the wholesale industry, primarily engaged in the sale of pharmaceuticals and medical devices, along with various other products [5]. Financial Reporting Basis - The financial statements are prepared based on the going concern assumption, indicating that the company has the ability to continue its operations for at least the next 12 months [6]. - The financial statements comply with the requirements of the accounting standards, providing a true and complete reflection of the company's financial status, operating results, and cash flows [6]. Accounting Policies and Estimates - The company uses the perpetual inventory system for its inventory management, valuing inventory at actual cost upon acquisition [22]. - The company recognizes financial assets and liabilities based on their classification, including those measured at amortized cost and those measured at fair value [10][12]. Financial Instruments - Financial assets are classified based on the business model for managing them and their contractual cash flow characteristics [6][10]. - The company applies the expected credit loss model for impairment accounting, assessing credit risk based on historical experience and current conditions [16][19]. Long-term Investments - Long-term equity investments are accounted for using the cost method for subsidiaries and the equity method for joint ventures and associates [26][27]. - The company evaluates its long-term investments based on the fair value of the underlying assets and adjusts the carrying amount accordingly [24][28].

Core Viewpoint - Huasheng Technology announced the approval of multiple proposals, including the performance commitment completion status of Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024 during the 23rd meeting of its 13th Board of Directors [2] Summary by Relevant Sections - Company Announcement - Huasheng Technology released an announcement on the evening of August 1, stating that its Board of Directors approved several proposals [2] - One of the key proposals discussed was related to the performance commitment completion status of Tibet Kangyu Pharmaceutical for the year 2024 [2]

Group 1 - The company announced the approval of the performance commitment completion for Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024 [2] - The company plans to publicly transfer 51% equity stake in Tibet Kangyu Pharmaceutical [2]

Group 1 - The company, Huasheng Technology, announced that it will hold its first extraordinary general meeting of shareholders on August 19, 2025 [1] - The agenda for the meeting includes the proposal to publicly transfer 51% equity of Tibet Kangyu [1]

Group 1 - The company, Huasheng Technology (000790.SZ), announced the intention to transfer 51% equity of its subsidiary, Tibet Kangyu, to focus resources on core business and enhance profitability and competitiveness [1] - The transfer will be conducted through a public listing at the Southwest United Property Exchange, with a starting price based on the asset evaluation agency's assessment, set at RMB 63.7806 million [1]

华神科技（000790）(000790.SZ)公告，公司拟通过公开挂牌转让公司控股子公司西藏康域药业有限公 司(简称"西藏康域")51%股权，挂牌底价为6378.06万元。公司本次股权转让将在西南联合产权交易所以 公开挂牌转让方式进行，交易受让方尚不能确定。 ...

四川华信(集团)会计师事务所 (特殊普通合伙) SI CHUAN HUA XIN (GROUP) CPA (LLP) 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 电话:(028) 85560449 传真:(028) 85560449 邮编:610041 电邮: schxzhb@hxcpa.com.cn 西藏康域药业有限公司 2024 年度年报审计报告 川华信审(2025)第 0055-011 号 目录: 1、审计报告 2、资产负债表、资产负债表(续) 3、利润表 4、现金流量表、现金流量表附表 5、所有者权益变动表、所有者权益变动表(续) 6、财务报表附注 此""""""此码用于证明该审计报告是否由具有执业许可 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mob 西藏康域药业有限公司 审计报告 审计报告 川华信审(2025)第 0055-011 号 三、管理层和治理层对财务报表的责任 西藏康域管理层负责按照企业会计准则的规定编制财务报表,使其实现公允反映，并设 计、执行和维护必要的内部控制，以使财务报表不存在由于舞弊或错误导致的重大错报。 在编制财务报表时,管理层负 ...

关于西藏康域药业有限公司 2024 年度业绩承诺实现情况 专项审核报告 川华信专(2025)第 0976 号 | 四川华信(集团)会计师事务所 地址:成都市洗面桥街 18号金茂礼都南 28楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | ST - 100円 - 100円 - 2020 - 100 (LLP) | 目录: 1、专项审核报告 2、专项说明 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 西藏康域药业有限公司 专项审核报告 关于西藏康域药业有限公司 2024 年度业绩承诺实现情况专项审核报告 川华信专(2025)第 0976 号 成都华神科技集团股份有限公司: 我们接受委托,对西藏康域药业有限公司(以下简称"西藏康域")管理层编制的《两 藏康域药业有限公司 2024 年度业绩承诺实现情况专项说明》进行了审核。 一、管理层的责任 编制《西藏康域药业有限公司 2024年度业绩承诺实现情况专项说明》,并保证其真实 性、完整性和准确性,提供真实、合法、完整的实物证据、原 ...

本报告依据中国资产评估准则编制 成都华神科技集团股份有限公司拟转让 所持有的西藏康域药业有限公司51%股权项目 涉及西藏康域药业有限公司股东全部权益价值 资产评估报告 沃克森评报字(2025)第1478号 （共一册 第一册） 沃克森（北京）国际资产评估有限公司 二〇二五年六月三十日 | 资产评估报告·声明 1 | | | --- | --- | | 资产评估报告·摘要 3 | | | 资产评估报告·正文 5 | | | 一、 委托人、被评估单位及资产评估委托合同约定的其他资产评估报告使用人...5 | | | 二、 评估目的 13 | | | 三、 评估对象和评估范围 13 | | | 四、 价值类型 15 | | | 五、 评估基准日 15 | | | 六、 评估依据 15 | | | 七、 | 评估方法 17 | | 八、 评估程序实施过程和情况 23 | | | 九、 评估假设 25 | | | 十、 评估结论 27 | | | 十一、 特别事项说明 30 | | | 十二、 资产评估报告使用限制说明 32 | | | 十三、 资产评估报告日 33 | | | 资产评估报告·附件 35 | | 成都华神 ...